Blueprint Medicines to Present Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 61st ASH Annual Meeting and Exposition

CAMBRIDGE, Mass., Nov. 6, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that an abstract for the ongoing Phase 2 PIONEER clinical trial evaluating avapritinib for the treatment of indolent and smoldering systemic mastocytosis has been accepted as a poster presentation at the 61^st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida on December 7-10, 2019. Initial results from the dose-finding portion (part 1) of the PIONEER trial will be reported in a Trial in Progress poster.   

The accepted abstract is listed below and now available on the ASH conference website: https://hematology.org/Annual-Meeting/.

Poster Title: Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy
Session Title: Myeloproliferative Syndromes: Clinical: Poster II
Session Date & Time: Sunday, December 8, 2019 from 6:00 – 8:00 p.m. ET
Presenter: Cem Akin, M.D., Ph.D.
Abstract Number: 2950

Investor Event and Webcast Information
Blueprint Medicines will host an investor event on Sunday, December 8, 2019 beginning at 8:30 p.m. ET in Orlando to review initial data from the PIONEER trial. The event will be webcast live and can be accessed under "Events and Presentations" in the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be available approximately two hours after the event and will be available for 30 days following the event.

About Blueprint Medicines
Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and development of new treatments and increases the likelihood of clinical success. We are currently advancing three investigational medicines in clinical development, along with multiple research programs. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.

SOURCE Blueprint Medicines

Related Links

http://www.blueprintmedicines.com